{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:52:49Z","timestamp":1785372769063,"version":"3.55.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015287","name":"Scholarship for Academic Leader of Yunnan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Chimeric antigen receptors (CARs) are genetically engineered fusion proteins composed of extracellular antigen-recognition domains and multiple intracellular signaling domains. Although CAR T-cell immunotherapy has achieved significant advancements in treating hematologic malignancies, its application against solid tumors remains less successful. Key challenges\u2014including production complexities, the scarcity of tumor-specific antigens, and limitations in cell trafficking and tumor infiltration\u2014continue to impede therapeutic efficacy. Natural killer (NK) cells, essential innate immune lymphocytes, play a critical role in targeting malignant cells. Their unique antigen-recognition mechanisms, potent cytotoxicity, and favorable clinical safety profile position CAR NK cells as a promising alternative for targeted cancer therapy, especially for solid tumors. However, the transient persistence of NK cells\n                    <jats:italic>in vivo<\/jats:italic>\n                    and the technical challenges associated with their preparation currently limit the broader clinical adoption of this approach. This review examines the advantages of CAR NK cells immunotherapy and synthesizes current domestic and international research to advance the understanding of CAR NK cells therapeutics.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1608277","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:22:47Z","timestamp":1761805367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy of chimeric antigen receptor NK cells: status and its promising future"],"prefix":"10.3389","volume":"16","author":[{"given":"Fang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2023.011","article-title":"Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia","volume":"46","year":"2023","journal-title":"Aust prescriber"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (London England)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet (London England)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/Refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet (London England)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4161\/onci.19458","article-title":"Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy","volume":"1","author":"Song","year":"2012","journal-title":"Oncoimmunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12139","article-title":"Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells","volume":"257","author":"Jensen","year":"2014","journal-title":"Immunol Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","article-title":"CAR-engineered NK cells; a promising therapeutic option for treatment of hematological Malignancies","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors","volume":"38","author":"MacKay","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"T\u00f6pfer","year":"2015","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","article-title":"2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell Malignancies","volume":"12","author":"Xu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.004549","article-title":"Natural killer cells induce distinct modes of cancer cell death: Discrimination, quantification, and modulation of apoptosis, necrosis, and mixed forms","volume":"293","author":"Backes","year":"2018","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.21037\/atm.2019.01.42","article-title":"NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives","volume":"7","author":"Lo Nigro","year":"2019","journal-title":"Ann Trans Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"key":"B34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-Specific NK cells for targeted therapy of glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J Natl Cancer Institute"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.06.014","article-title":"Superior expansion and cytotoxicity of human primary NK and CAR-NK cells from various sources via enriched metabolic pathways","volume":"18","author":"Yang","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.64630","article-title":"Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer","volume":"17","author":"Cao","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115899","article-title":"CAR-NK cells in the treatment of solid tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"18729","DOI":"10.1038\/s41598-019-55239-y","article-title":"Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells","volume":"9","author":"Herrera","year":"2019","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00329","article-title":"Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications","volume":"8","author":"Sarvaria","year":"2017","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2011.12.015","article-title":"The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation","volume":"73","author":"Luevano","year":"2012","journal-title":"Hum Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2014.01.014","article-title":"Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells","volume":"2","author":"Valamehr","year":"2014","journal-title":"Stem Cell Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002866","article-title":"NK cells enhance CAR-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR-T cell fitness","volume":"9","author":"Bachiller","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03123","article-title":"High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-Specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia","volume":"10","author":"M\u00fcller","year":"2019","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-4622(02)00057-1","article-title":"Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes","volume":"97","author":"Davis","year":"2002","journal-title":"Biophys Chem"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1038\/mtna.2013.17","article-title":"Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells","volume":"2","author":"Fenard","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2012.080","article-title":"Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy","volume":"23","author":"Sutlu","year":"2012","journal-title":"Hum Gene Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.000414","article-title":"Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation","volume":"284","author":"Clark","year":"2009","journal-title":"J Biol Chem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.03.017","article-title":"Rosuvastatin enhances VSV-G lentiviral transduction of NK cells via upregulation of the low-density lipoprotein receptor","volume":"17","author":"Gong","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-Cell transduction with baboon envelope pseudotyped lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02001","article-title":"A distinct subset of highly proliferative and lentiviral vector (LV)-transducible NK cells define a readily engineered subset for adoptive cellular therapy","volume":"10","author":"Bari","year":"2019","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-Engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0207","article-title":"intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors","volume":"6","author":"Oei","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00402","article-title":"Dysregulation of chemokine\/chemokine receptor axes and NK cell tissue localization during diseases","volume":"7","author":"Bernardini","year":"2016","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1\u03b1-secreting glioblastoma","volume":"38","author":"M\u00fcller","year":"2015","journal-title":"J immunother (Hagerstown Md: 1997)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","article-title":"CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR NK cells in mice with peritoneal xenografts","volume":"16","author":"Ng","year":"2020","journal-title":"Mol Ther oncolytics"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.02.006","article-title":"CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma","volume":"24","author":"Schomer","year":"2022","journal-title":"Cytotherapy"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202005934","article-title":"Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-Cell lymphoma therapy","volume":"60","author":"Hong","year":"2021","journal-title":"Angewandte Chemie (International ed English)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell communication signaling: CCS"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2016.10.016","article-title":"Hypoxia-inducible factors: master regulators of cancer progression","volume":"2","author":"Schito","year":"2016","journal-title":"Trends Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M503714200","article-title":"Involvement of transforming growth factor-beta 1 signaling in hypoxia-induced tolerance to glucose starvation","volume":"280","author":"Suzuki","year":"2005","journal-title":"J Biol Chem"},{"key":"B69","doi-asserted-by":"publisher","first-page":"21520","DOI":"10.1038\/srep21520","article-title":"Induction of WNT11 by hypoxia and hypoxia-inducible factor-1\u03b1 regulates cell proliferation, migration and invasion","volume":"6","author":"Mori","year":"2016","journal-title":"Sci Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802047105","article-title":"Notch signaling mediates hypoxia-induced tumor cell migration and invasion","volume":"105","author":"Sahlgren","year":"2008","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142116","article-title":"Targeting the \u03b1v integrin\/TGF-\u03b2 axis improves natural killer cell function against glioblastoma stem cells","volume":"131","author":"Shaim","year":"2021","journal-title":"J Clin Invest"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-1023","article-title":"PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress","volume":"10","author":"Klopotowska","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02354","article-title":"The rise of NK cell checkpoints as promising therapeutic targets in cancer immunotherapy","volume":"10","author":"Sun","year":"2019","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-021-10246-3","article-title":"Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects","volume":"17","author":"Elahi","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell Malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B81","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"New Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.88539","article-title":"NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer","volume":"20","author":"Li","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05851-y","article-title":"Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer","volume":"22","author":"Torchiaro","year":"2024","journal-title":"J Trans Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1101\/2023.07.11.548344","article-title":"Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer","volume":"14","author":"Murali Shankar","year":"2023","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24109038","article-title":"Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer","volume":"24","author":"Raftery","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1290488","article-title":"CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma","volume":"14","author":"Ciulean","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608277\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:22:48Z","timestamp":1761805368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1608277\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2025.1608277"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1608277","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"1608277"}}